CTOR

7.73% -0.0819

Dopo l'orario di chiusura: .99 0.0119 +1.22%

Citius Oncology Inc (CTOR)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1176)

(347) 627-0058

420 LEXINGTON AVE,, NEW YORK

Prossima data di guadagno

Ultimi documenti SEC

CTOR's Discussions on Twitter

Confronta CTOR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTOR Citius Oncology Inc	0.9781	69.74M	0	0	0	0.00
ZTS Zoetis Inc	164.84	74.37B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.69	43.81B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.10	41.53B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	22.09	25.03B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	12.52	14.94B	15.05B	-883.30M	1.89B	-0.74

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-27	Iniziato	Maxim Group	Buy

Citius Oncology Inc Borsa (CTOR) Ultime notizie

Citius Oncology Inc Azioni (CTOR) Dati Finanziari

Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Confronta CTOR con altri titoli

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Borsa (CTOR) Ultime notizie

Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart

Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World

Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan

CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada

CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma

CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India

CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com

Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com

Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex

Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News

Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada

CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow

A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News

Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com

Citius Oncology Inc. (CTOR) requires closer examination - US Post News

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks

CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle

Citius Oncology Inc Azioni (CTOR) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a CTOR